Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2023 And To Consider And Recommend Dividend, If Any, On Equity Shares For The Year Ended March 31, 2023.

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2023 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2023. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2023 to May 21, 2023 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31, 2023.
03-05-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Minutes Of The Resolution Passed By Way Of Postal Ballot Through Remote E-Voting Process

 With reference to the captioned subject, we are enclosing the certified copy of Minutes of the resolution passed by way of Postal Ballot through remote e-voting process by the Shareholders of the Company on 14th April, 2023. The Results of the Postal Ballot were declared on 14th April, 2023. Request you to kindly take the same on record.
02-05-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd.

 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd.
26-04-2023

Glenmark to pay $87.5 mn to settle lawsuits over a generic drug in US

 Glenmark Pharmaceuticals on Tuesday it will pay USD 87.5 million to three plaintiff groups to settle multiple antitrust and consumer protection lawsuits in the US related to a generic drug. There were multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia against the company and its subsidiary Glenmark Pharmaceuticals Inc. in connection with generic Zetia, a drug for the treatment of cholesterol, the Mumbai-based drug maker said in a regulatory filing. The lawsuits alleged that in 2010, Glenmark entered an anticompetitive agreement to settle patent infringement litigation involving a patent related to ezetimibe (the active ingredient in Zetia) with Schering Corporation and MSP Singapore Company LLC. The trial for the case began on April 19, 2023 in the US courts. Three plaintiff groups collectively representing all of the claims against the company and Merck are referred to as the Direct Purchaser Plaintiffs,
25-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd. (Hereinafter Referred As 'The Company')

 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd. (hereinafter referred as 'the Company')
25-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
19-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGLENMARK PHARMACEUTICALS LTD. 2CIN NO.L24299MH1977PLC019982 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harish Kuber Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: VS Mani Designation: Executive Director and Global Chief Financial Officer EmailId: [email protected] Date: 17/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
17-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company GLENMARK PHARMACEUTICALS LTD. 2 CIN NO. L24299MH1977PLC019982 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2020-21, 2021-22 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2020-21, 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harish KuberDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- VS Mani Designation : -Executive Director and Global Chief Financial Officer Date: 17/04/2023
17-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Result Of Postal Ballot & Scrutinizer'S Report

 Further to our letter dated 15th March, 2023 regarding notice of Postal Ballot, please find enclosed herewith the following - 1. Voting Result as required under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and 2. Scrutinizer's Report dated 14 April, 2023. Based on the Scrutinizer's Report, we wish to inform you that the Special Resolution mentioned in the said Postal Ballot notice has been passed by the members of the Company with requisite majority. The voting result along with the Scrutinizer's Report is also being made available on the Company's website.
14-04-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Global Asset Management (Hong Kong) Ltd
12-04-2023
Next Page
Close

Let's Open Free Demat Account